Exelixis to present data from phase 1 trials of XL647, XL880 and XL999 in cancer at oncology meeting

By Lisa Kerner

Erie, Pa., May 25 - Exelixis, Inc. said three abstracts containing data from its phase 1 clinical trials of XL647, XL880 and XL999 have been accepted at the 2006 American Society of Clinical Oncology Annual Meeting in Atlanta.

"Data from these phase 1 trials have provided the solid foundation on which to build our phase 2 clinical programs for XL647, XL880 and XL999," president and chief executive officer George A. Scangos said in a company news release.

"Six phase 2 trials of XL999 are ongoing and the phase 2 clinical trial programs for XL647 and XL880 are expected to initiate this summer."

XL647 inhibits multiple receptor tyrosine kinases (RTKs) involved in tumor cell proliferation and tumor vascularization (blood vessel formation). The orally available small molecule compound XL880 targets multiple RTKs implicated in the development, progression and spread of multiple cancers. XL999 inhibits RTKs associated with the development and maintenance of tumor vasculature and in the proliferation of some tumor cells.

Located in South San Francisco, Calif., Exelixis discovers and develops novel therapeutics for cancer and other serious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.